Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
AMEX
Asterias Biotherapeutics Common Series A (AST)
Asterias Biotherapeutics Common Series A (AST) Actualités

AST

Asterias Biotherapeutics, Inc. (AST)

Asterias Biotherapeutics Common Series A

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:AMEX:AST

1 2 3 4 5 6 7 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
20/03/2019	22h07	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(b) (15-12b)	AMEX:AST	Asterias Biotherapeutics Common Series A
20/03/2019	11h02	Edgar (US Regulatory)	Notice of Effectiveness (effect)	AMEX:AST	Asterias Biotherapeutics Common Series A
14/03/2019	19h55	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	AMEX:AST	Asterias Biotherapeutics Common Series A
14/03/2019	19h55	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	AMEX:AST	Asterias Biotherapeutics Common Series A
12/03/2019	22h00	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	AMEX:AST	Asterias Biotherapeutics Common Series A
12/03/2019	21h52	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	AMEX:AST	Asterias Biotherapeutics Common Series A
08/03/2019	22h07	Edgar (US Regulatory)	Current Report Filing (8-k)	AMEX:AST	Asterias Biotherapeutics Common Series A
08/03/2019	21h18	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...	AMEX:AST	Asterias Biotherapeutics Common Series A
01/03/2019	22h34	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	AMEX:AST	Asterias Biotherapeutics Common Series A
04/02/2019	23h26	Edgar (US Regulatory)	Proxy Statement - Merger or Acquistion (definitive) (defm14a)	AMEX:AST	Asterias Biotherapeutics Common Series A
24/01/2019	13h00	GlobeNewswire Inc.	Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	AMEX:AST	Asterias Biotherapeutics Common Series A
04/01/2019	14h00	GlobeNewswire Inc.	BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech...	AMEX:AST	Asterias Biotherapeutics Common Series A
27/11/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small C...	AMEX:AST	Asterias Biotherapeutics Common Series A
09/11/2018	22h10	GlobeNewswire Inc.	Asterias Biotherapeutics Reports Third Quarter Results	AMEX:AST	Asterias Biotherapeutics Common Series A
09/11/2018	22h04	Edgar (US Regulatory)	Quarterly Report (10-q)	AMEX:AST	Asterias Biotherapeutics Common Series A
08/11/2018	12h35	Business Wire	BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company	AMEX:AST	Asterias Biotherapeutics Common Series A
08/11/2018	12h30	Business Wire	BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update	AMEX:AST	Asterias Biotherapeutics Common Series A
02/11/2018	12h00	GlobeNewswire Inc.	Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018	AMEX:AST	Asterias Biotherapeutics Common Series A
31/10/2018	14h45	GlobeNewswire Inc.	Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study	AMEX:AST	Asterias Biotherapeutics Common Series A
01/10/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics Announces Facilities and IP License Option Agreements	AMEX:AST	Asterias Biotherapeutics Common Series A
20/09/2018	13h00	GlobeNewswire Inc.	FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Cli...	AMEX:AST	Asterias Biotherapeutics Common Series A
12/09/2018	13h00	GlobeNewswire Inc.	Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	AMEX:AST	Asterias Biotherapeutics Common Series A
04/09/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 ...	AMEX:AST	Asterias Biotherapeutics Common Series A
29/08/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR He...	AMEX:AST	Asterias Biotherapeutics Common Series A
09/08/2018	22h10	GlobeNewswire Inc.	Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress	AMEX:AST	Asterias Biotherapeutics Common Series A
31/07/2018	13h00	GlobeNewswire Inc.	Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	AMEX:AST	Asterias Biotherapeutics Common Series A
26/07/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018	AMEX:AST	Asterias Biotherapeutics Common Series A
17/07/2018	13h00	GlobeNewswire Inc.	Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	AMEX:AST	Asterias Biotherapeutics Common Series A
12/07/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Strok...	AMEX:AST	Asterias Biotherapeutics Common Series A
11/07/2018	13h00	GlobeNewswire Inc.	Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Cli...	AMEX:AST	Asterias Biotherapeutics Common Series A

Showing the most relevant articles for your search:AMEX:AST

1 2 3 4 5 6 7 Suivant >>

Credit Agricole

Lvmh Moet Hennessy Louis...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales